Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment

Summary

The purpose of this study is to determine the effectiveness and safety of triamcinolone acetonide in patients with serous pigment detachment associated with age-related macular degeneration

Conditions

• Age-Related Macular Degeneration

Interventions

PROCEDURE

Subtenon injection of 40 mg triamcinolone acetonide

Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.

PROCEDURE

Intravitreal injection of 4 mg triamcinolone acetonide

Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.

DIAGNOSTIC_TEST

Visometry

Ophthalmic examination

DIAGNOSTIC_TEST

Fluorescent angiography

Ophthalmic examination

DIAGNOSTIC_TEST

Refractometry

Ophthalmic examination

DIAGNOSTIC_TEST

Slit lamp examination

Ophthalmic examination

DIAGNOSTIC_TEST

Ophthalmoscopy

Ophthalmic examination

DIAGNOSTIC_TEST

OKT

Ophthalmic examination

DIAGNOSTIC_TEST

IOP

Ophthalmic examination

Sponsors & Collaborators

• Odessa National Medical University

  collaborator OTHER

• Mykolaiv Region Ophthalmogical Hospital

  collaborator OTHER

• Central Polyclinic of Internal Affairs of Ukraine

  collaborator OTHER_GOV

• The Filatov Institute of Eye Diseases and Tissue Therapy

  lead OTHER

Principal Investigators

• Andrii MD Korol, PhD · The Filatov Institute of Eye Diseases and Tissue Therapy

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

50 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-03-27

Primary Completion

2020-07-01

Completion

2020-12-31

Countries

• Ukraine

Study Locations